Tallaght University Hospital — Clinical Trial Site

67 Registered trials

35 Currently recruiting

Organisation

Tallaght University Hospital

Location

Dublin 24, Ireland

Identifier

ORG-100032750

Address

Tallaght, D24 NR0A, Ireland

Departments

4801: Clinical Research Facility
8044: Clinical Trial Center
Age Related Healthcare
Clinical Medicine
Clinical Trials Unit
Cognitive Clinical Trials Unit
Critical Care
Department of Medical Oncology
Gastroenterology
Haematology
ICU
Intensive Care Unit
Medical Oncology
Neurology
Oncology
Oncology (TUH)
Oncology Day Unit
Oncology Day Ward
Oncology department
Oncology Haematology Clinical Trials
Oncology/Haematology Clinical Trials
Pulmonary Medicine
Respiratory
Respiratory Medicine
Stroke
Tallaght
Urology

Clinical trials at this site (67)

Search interface

CheckMate 274 Ended

2022-500630-29-00 Subjects with High Risk Invasive Urothelial Carcinoma 5 2016-05-06
Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) Ended

2023-507889-89-00 Respiratory tract infection 5 2016-02-19
A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly sympto… Ended

2023-510453-41-00 Castration resistant prostate cancer patients metastati 5 2015-10-26
Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: ENZAMET Ended

2024-516137-13-00 Metastatic Prostate Cancer 5 2014-12-18
A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered i… Ended

2023-506696-10-00 Non-Small Cell Lung Cancer 5 2024-06-18
"Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (MIRANDA)" Ended

2023-505543-39-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2024-02-12
A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects With Metastatic or Local… Ended

2024-513870-23-00 Locally Advanced or Metastatic Unresectable Urothelial 5 2021-06-28
European DisCoVeRy for Solidarity: An Adaptive Pandemic and Emerging Infection Platform Trial (SolidAct) Ended

2022-500385-99-00 SARS-CoV II infection (Coronavirus disease) 5 2021-06-03
A Study of Subcutaneous Nivolumab in Previously Treated Advanced or Metastatic Clear Cell Renal Cell Carcinoma Ended

2023-503280-42-00 Metastatic Clear Cell Renal Cell Carcinoma 5 2021-06-01
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) Ended

2023-506918-45-00 Mild cognitive impairment (MCI) or mild dementia, both 5 2021-05-17
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) Ended

2023-506919-18-00 Mild cognitive impairment (MCI) or mild dementia, both 5 2021-05-17
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's … Ended

2023-504991-31-00 Agitation in Patients With Dementia of the Alzheimer's 5 2021-05-06
Phase 3 Study of Pembrolizumab/Placebo plus Enzalutamide plus ADT in mHSPC Ended

2023-507024-24-00 Metastatic hormone sensitive prostate cancer 5 2020-05-05
Pembrolizumab or Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced Ended

2023-506657-38-00 Biliary Tract Carcinoma 5 2019-10-02
A global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eli… Ended

2022-501970-20-01 Cis-eligible Muscle-invasive bladder cancer. 5 2019-06-07
Pembrolizumab/placebo plus chemotherapy as first-line therapy in participants with HER2 negative advanced gastric or GEJ adenocarcinoma Ended

2023-508890-10-00 Gastric and gastric esophageal junction (GEJ) adenocarc 5 2018-12-05
Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in HER2 Positive Advanced Gastric or GEJ Adenocarcinoma Ended

2023-508253-98-00 Gastric or gastroesophageal junction (GEJ) adenocarcino 5 2018-10-05
Pembrolizumab in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma Ended

2023-507294-18-00 Metastatic renal cell carcinoma 5 2016-09-16
A Phase 3 Study of Nivolumab plus Ipilimumab Versus Sunitinib in untreated Subjects with Advanced or Metastatic Renal Cell Carcinoma (RCC) Ended

2023-504761-23-00 Advanced or metastatic renal cell carcinoma 5 2014-11-19